-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-513122-27-00
5
2025-06-10
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-514465-18-00
9
2025-04-23
Advanced or Metastatic Non-Squamous NSCLC
-
2024-517284-23-00
5
2025-04-23
Active Psoriatic Arthritis
-
2024-513053-69-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2024-516363-92-00
5
2025-04-08
Psychosis Associated with Alzheimer’s Disease
-
2023-509070-36-00
5
2025-03-18
Major Depressive Disorder with Insomnia Symptoms
-
2024-515020-36-00
9
2025-02-24
Advanced Solid tumour
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-513853-66-00
5
2025-02-04
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
-
2023-509482-20-00
4
2024-12-03
Solid Tumors
-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus
-
2022-502972-22-00
5
2024-10-31
Clostridioides difficile infection.
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2023-508760-29-00
5
2024-10-21
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-508581-15-00
5
2024-10-08
Heart condition
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2024-511309-47-00
4
2024-07-17
moderate thrombocytopenia
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck